Cover Image
市場調查報告書

PharmaPoint:類風濕性關節炎 - 全球醫藥品的預測與市場分析

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 296460
出版日期 內容資訊 英文 486 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:類風濕性關節炎 - 全球醫藥品的預測與市場分析 PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023
出版日期: 2014年12月31日 內容資訊: 英文 486 Pages
簡介

類風濕性關節炎是慢性自體免疫症的一種,會造成關節部位發炎和變形。全球主要10國的患者總數,目前約有700萬以上,推計到2023年將達到850萬人。抗TNF藥對於治療類風濕性關節炎的症狀·徵兆、抑制發炎性骨骼疾病的惡化上相當有效。但生技仿製藥和新生技藥品,以及被稱為JAK抑制劑的口服治療藥級的出現,一認為市場環境在今後十年將會產生急劇的變化。抗TNF藥本身是非常有效的治療藥,但對新加入企業而言市場卻是競爭極度激烈化,再加上生技仿製藥的認證·上市,競爭壓力更是日益高升。

本報告提供全球類風濕性關節炎治療藥市場相關調查分析,提供您疾病概要,收益實際成果與預測,主要專題 (策略性競爭企業評估,市場特性,未滿足需求,臨床試驗製圖等),再加上開發平台分析,現在/未來市場競爭分析 (推動因素·阻礙因素,課題等) 等資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
  • 症狀
  • 預後
  • 生活品質 (QoL)

第4章 流行病學

  • 疾病的背景
  • 危險因素和併發症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法:類風濕性關節炎的患者總數
    • 預測的前提條件與手法:類風濕性關節炎已診斷患者數
  • 類風濕性關節炎的流行病學預測
    • 類風濕性關節炎的患者總數
    • 類風濕性關節炎的各年齡患者數
    • 類風濕性關節炎的男女患者數
    • 類風濕性關節炎已診斷的患者數
    • 類風濕性關節炎已診斷的患者數 (年齡已調整)
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病管理

  • 診斷及治療概要
    • 診斷
    • 治療的指南
    • 治療類風濕性關節炎用有代表性的處方藥
    • 臨床診療
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 澳洲
  • 中國
  • 印度

第6章 競爭評估

  • 概要
  • 產品簡介:領導品牌
    • Enbrel (依那西普(Etanercept))
    • Humira (Adalimumab)
    • Remicade (Infliximab)
    • Simponi (golimumab)
    • Cimzia (certolizumab pegol)
    • 6.2.6Orencia (abatacept)
    • actemraRoActemra (tocilizumab)
    • Rituxan/MabThera (Rituximab)
    • Inflectra/Remsima (Infliximab生技仿製藥)
    • Xeljanz (tofacitinib)
    • iguratimod/t-614
    • Methotrexate (許多品牌)
  • 生技仿製藥
    • 簡介
    • 在主要自體免疫疾病方面,Hospira的Inflectra和J & J的Remicade的比較
    • 免疫學機構團體的生技仿製藥
    • 開發中的生技仿製藥的數量
    • 製藥產業整體所感受到的生技仿製藥影響度
    • 類風濕性關節炎用生技仿製藥的普及率預計將依市場而有所不同
    • 生技仿製藥的預測
  • 其他治療方法

第7章 未滿足需求及機會

  • 概要
  • 開發高成本效率的治療方法
    • 未滿足需求
    • 差距分析
    • 機會
  • 預測治療反應度用的生物標記
  • 類風濕性關節炎的早期診斷
  • 個體化治療的方法

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
    • 臨床實驗:各級
  • 臨床實驗階段的有潛力的藥劑
    • Sarilumab
    • Sirukumab
    • Clazakizumab
    • Cosentyx (secukinumab)
    • Tregalizumab
    • Mavrilimumab
    • Denosumab (Prolia/Xgeva)
    • barishichinibu
    • Peficitinib
    • Decernotinib
    • Filgotinib
    • Masitinib
    • raVAX
  • 開發中的其他藥劑

第9章 現在及未來的主要企業

  • 企業策略趨勢
  • 企業簡介
    • AbbVie
    • Pfizer
    • Amgen
    • Johnson & Johnson
    • Eli Lilly
    • Bristol-Myers Squibb
    • UCB
    • Roche
    • GlaxoSmithKline
    • Novartis
    • Sanofi
    • AstraZeneca-MedImmune
    • Astellas Pharma Inc.
    • Vertex
    • 第一三共

第10章 市場預測

  • 全球市場
    • 預測
    • 推動因素及課題:全球問題
  • 美國
    • 預測
    • 主要的活動
    • 推動因素及障礙
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 澳洲
  • 中國
  • 印度

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC93PIDR

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Highlights

Key Questions Answered

  • How large an impact will biosimilars have on the RA market? What do rheumatologists and key opinion leaders across the 10MM think about the evolving RA treatment landscape?
  • How is the uptake of JAK inhibitors expected to affect the global RA market?
  • Which novel biologics are the most promising? How are product launches expected to affect the anti-TNFs?
  • According to KOLs, what are the most important unmet needs in RA? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2023?
  • What governmental and industry developments are likely to affect sales of the top-selling RA drugs in the markets researched? Which is the largest growth market globally?

Key Findings

  • Biosimilars are expected to change the landscape for RA and create pricing pressure in the RA market. However, questions from physicians and regulators regarding the appropriate use of biosimilars still lingers.
  • Sales of anti-TNFs are expected to decline due to the introduction of biosimilars and other novel biologics and small molecules to treat RA.
  • Developers of pipeline products will need strong clinical data and a clear development and commercialization strategy to penetrate the competitive RA market.
  • The market will continue to be dominated by Big Pharma who will leverage their R&D, manufacturing, and distribution networks.

Scope

  • Overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
  • Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the RA biologics and biosimilars markets.
  • Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte's baricitinib), novel biologics (such as AstraZeneca-MedImmune's mavrilimumab), and biosimilars (such as Celltrion/Hospira/Alvogen's Inflectra/Remsima).
  • Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the RA market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global RA market from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
    • 4.3.4. Australia
    • 4.3.5. China
    • 4.3.6. India
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods - Total Prevalent Cases of RA
    • 4.4.4. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of RA
  • 4.5. Epidemiological Forecast for RA (2013-2023)
    • 4.5.1. Total Prevalent Cases of RA
    • 4.5.2. Age-Specific Total Prevalent Cases of RA
    • 4.5.3. Sex-Specific Total Prevalent Cases of RA
    • 4.5.4. Diagnosed Prevalent Cases of RA
    • 4.5.5. Age-Standardized Diagnosed Prevalence of RA
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines
    • 5.1.3. Leading Prescribed Drugs for the Treatment of RA
    • 5.1.4. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan
  • 5.9. Australia
  • 5.10. China
  • 5.11. India

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands
    • 6.2.1. Enbrel (etanercept)
    • 6.2.2. Humira (adalimumab)
    • 6.2.3. Remicade (infliximab)
    • 6.2.4. Simponi (golimumab)
    • 6.2.5. Cimzia (certolizumab pegol)
    • 6.2.6. Orencia (abatacept)
    • 6.2.7. Actemra/RoActemra (tocilizumab)
    • 6.2.8. Rituxan/MabThera (rituximab)
    • 6.2.9. Inflectra/Remsima (infliximab biosimilar)
    • 6.2.10. Xeljanz (tofacitinib)
    • 6.2.11. Iguratimod/T-614
    • 6.2.12. Methotrexate (Numerous Brands)
  • 6.3. Biosimilars
    • 6.3.1. Introduction
    • 6.3.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 6.3.3. Biosimilars in the Immunology Community
    • 6.3.4. By the Numbers: Biosimilars in Development
    • 6.3.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
    • 6.3.6. Uptake of Biosimilars for RA is Expected to Vary by Market
    • 6.3.7. Biosimilars' Forecast
  • 6.4. Other Therapies

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Development of Cost-Effective Therapies
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Biomarkers to Predict Responsiveness to Therapy
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Early Diagnosis of RA
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Personalized Treatment Approach
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Class
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Sarilumab
    • 8.3.2. Sirukumab
    • 8.3.3. Clazakizumab
    • 8.3.4. Cosentyx (secukinumab)
    • 8.3.5. Tregalizumab
    • 8.3.6. Mavrilimumab
    • 8.3.7. Denosumab (Prolia/Xgeva)
    • 8.3.8. Baricitinib
    • 8.3.9. Peficitinib
    • 8.3.10. Decernotinib
    • 8.3.11. Filgotinib
    • 8.3.12. Masitinib
    • 8.3.13. RAVAX
  • 8.4. Other Drugs in Development

9. Current and Future Players

  • 9.1. Trends in Corporate Strategy
  • 9.2. Company Profiles
    • 9.2.1. AbbVie
    • 9.2.2. Pfizer
    • 9.2.3. Amgen
    • 9.2.4. Johnson & Johnson
    • 9.2.5. Eli Lilly
    • 9.2.6. Bristol-Myers Squibb
    • 9.2.7. UCB
    • 9.2.8. Roche
    • 9.2.9. GlaxoSmithKline
    • 9.2.10. Novartis
    • 9.2.11. Sanofi
    • 9.2.12. AstraZeneca- MedImmune
    • 9.2.13. Astellas
    • 9.2.14. Vertex
    • 9.2.15. Daiichi Sankyo

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. Australia
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers
  • 10.10. China
    • 10.10.1. Forecast
    • 10.10.2. Key Events
    • 10.10.3. Drivers and Barriers
  • 10.11. India
    • 10.11.1. Forecast
    • 10.11.2. Key Events
    • 10.11.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed RA Patients
    • 11.4.2. Percentage of Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic and Biosimilar Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for This Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Reviewer
    • 11.7.3. Therapy Area Director
    • 11.7.4. Epidemiologist
    • 11.7.5. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Symptoms of RA
  • Table 2: Risk Factors and Comorbidities for RA
  • Table 3: 1987 ACR Diagnostic Criteria for RA
  • Table 4: 10MM, Sources of RA Prevalence Data
  • Table 5: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 6: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N (Row %), 2013
  • Table 7: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N (Row %), 2013
  • Table 8: 10MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 9: 1987 ACR Diagnostic Criteria for RA
  • Table 10: 2010 ACR/EULAR Diagnostic Criteria for RA
  • Table 11: Treatment Guidelines for RA Used by Each Country in the 10MM
  • Table 12: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity
  • Table 13: EULAR 2013 Criteria for RA Remission
  • Table 14: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014
  • Table 15: RA Treatment Country Profile - US
  • Table 16: RA Treatment Country Profile - France
  • Table 17: RA Treatment Country Profile - Germany
  • Table 18: RA Treatment Country Profile - Italy
  • Table 19: RA Treatment Country Profile - Spain
  • Table 20: RA Treatment Country Profile - UK
  • Table 21: RA Treatment Country Profile - Japan
  • Table 22: RA Treatment Country Profile - Australia
  • Table 23: RA Treatment Country Profile - China
  • Table 24: RA Treatment Country Profile - India
  • Table 25: Leading Branded Treatments for RA 2014
  • Table 26: Product Profile - Enbrel
  • Table 27: 10-Year, Open-Label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 Years for Completers
  • Table 28: 10-year, Open-Label Safety and Efficacy Trial of Enbrel: Overall Safety Results
  • Table 29: Enbrel SWOT Analysis, 2014
  • Table 30: Global Sales Forecasts ($m) for Enbrel, 2013-2023
  • Table 31: Product Profile - Humira
  • Table 32: Humira SWOT Analysis, 2014
  • Table 33: Global Sales Forecasts ($m) for Humira, 2013-2023
  • Table 34: Product Profile - Remicade
  • Table 35: Remicade SWOT Analysis, 2014
  • Table 36: Global Sales Forecasts ($m) for Remicade, 2013-2023
  • Table 37: Product Profile - Simponi
  • Table 38: Simponi SWOT Analysis, 2014
  • Table 39: Global Sales Forecasts ($m) for Simponi, 2013-2023
  • Table 40: Product Profile - Cimzia
  • Table 41: Cimzia SWOT Analysis, 2014
  • Table 42: Global Sales Forecasts ($m) for Cimzia, 2013-2023
  • Table 43: Product Profile - Orencia
  • Table 44: Orencia SWOT Analysis, 2014
  • Table 45: Global Sales Forecasts ($m) for Orencia, 2013-2023
  • Table 46: Product Profile - Actemra
  • Table 47: Actemra SWOT Analysis, 2014
  • Table 48: Global Sales Forecasts ($m) for Actemra, 2013-2023
  • Table 49: Product Profile - Rituxan
  • Table 50: Rituxan SWOT Analysis, 2014
  • Table 51: Global Sales Forecasts ($m) for Rituxan, 2013-2023
  • Table 52: Product Profile - Inflectra/Remsima
  • Table 53: Inflectra/Remsima SWOT Analysis, 2014
  • Table 54: Product Profile - Xeljanz
  • Table 55: ORAL Standard ACR20 Responses for Tofacitinib vs. Humira and Placebo at Month 6
  • Table 56: ORAL Step ACR20, 50, and 70 Responses for Xeljanz vs. Placebo at Month 6
  • Table 57: Xeljanz SWOT Analysis, 2014
  • Table 58: Global Sales Forecasts ($m) for Xeljanz, 2013-2023
  • Table 59: Product Profile - Iguratimod
  • Table 60: Iguratimod SWOT Analysis, 2014
  • Table 61: Global Sales Forecasts ($m) for Iguratimod, 2013-2023
  • Table 62: Product Profile - MTX
  • Table 63: MTX SWOT Analysis, 2014
  • Table 64: Global Sales Forecasts ($m) for MTX, 2013-2023
  • Table 65: Biosimilars Pipeline for RA, 2013
  • Table 66: Physician Uptake of Biosimilar Products for RA Across the 10MM, 2014
  • Table 67: Global Sales Forecasts ($m) for Etanercept Biosimilars, 2013-2023
  • Table 68: Global Sales Forecasts ($m) for Adalimumab Biosimilars, 2013-2023
  • Table 69: Global Sales Forecasts ($m) for Infliximab Biosimilars, 2013-2023
  • Table 70: Global Sales Forecasts ($m) for Certolizumab Pegol Biosimilars, 2013-2023
  • Table 71: Global Sales Forecasts ($m) for Abatacept Biosimilars, 2013-2023
  • Table 72: Global Sales Forecasts ($m) for Tocilizumab Biosimilars, 2013-2023
  • Table 73: Global Sales Forecasts ($m) for Rituximab Biosimilars, 2013-2023
  • Table 74: Summary of Minor Therapeutic Drug Classes Used to Treat RA, 2014
  • Table 75: Unmet Need and Opportunity in RA, 2014
  • Table 76: Comparison of Therapeutic Drug Classes in Development for RA, 2014
  • Table 77: Product Profile - Sarilumab
  • Table 78: MOBILITY Study Part, A, Results for Sarilumab at Week 12
  • Table 79: MOBILITY Study, Part B, Results for Sarilumab at Week 52
  • Table 80: Sarilumab SWOT Analysis, 2014
  • Table 81: Global Sales Forecasts ($m) for Sarilumab, 2013-2023
  • Table 82: Product Profile - Sirukumab
  • Table 83: Sirukumab SWOT Analysis, 2014
  • Table 84: Global Sales Forecasts ($m) for Sirukumab, 2013-2023
  • Table 85: Product Profile - Clazakizumab
  • Table 86: Phase IIb Study of Clazakizumab: ACR Responses After 12 Weeks
  • Table 87: Phase IIb Study of Clazakizumab: ACR Responses After 24 Weeks
  • Table 88: Clazakizumab SWOT Analysis, 2014
  • Table 89: Global Sales Forecasts ($m) for Clazakizumab, 2013-2023
  • Table 90: Product Profile - Cosentyx
  • Table 91: Cosentyx SWOT Analysis, 2014
  • Table 92: Global Sales Forecasts ($m) for Cosentyx, 2013-2023
  • Table 93: Product Profile - Tregalizumab
  • Table 94: Tregalizumab SWOT Analysis, 2014
  • Table 95: Global Sales Forecasts ($m) for Tregalizumab, 2013-2023
  • Table 96: Product Profile - Mavrilimumab
  • Table 97: Mavrilimumab SWOT Analysis, 2014
  • Table 98: Global Sales Forecasts ($m) for Mavrilimumab, 2013-2023
  • Table 99: Product Profile - Denosumab
  • Table 100: Denosumab SWOT Analysis, 2014
  • Table 101: Global Sales Forecasts ($m) for denosumab in RA, 2013-2023
  • Table 102: Product Profile - Baricitinib
  • Table 103: Baricitinib Phase IIb Trial, Part A: ACR Responses at Week 12
  • Table 104: Baricitinib Phase IIb Trial, Part B: ACR Responses at Weeks 24 and 52
  • Table 105: Baricitinib Phase IIb Trial, Part A: Safety at Week 12
  • Table 106: Baricitinib Phase IIb Trial, Part A, Laboratory Values at Week 12
  • Table 107: Baricitinib SWOT Analysis, 2014
  • Table 108: Global Sales Forecasts ($m) for Baricitinib, 2013-2023
  • Table 109: Product Profile - Peficitinib
  • Table 110: Peficitinib SWOT Analysis, 2014
  • Table 111: Global Sales Forecasts ($m) for Peficitinib, 2013-2023
  • Table 112: Product Profile - Decernotinib
  • Table 113: Phase IIb tudy of Decernotinib: ACR Responses at Week 24
  • Table 114: Decernotinib SWOT Analysis, 2014
  • Table 115: Global Sales Forecasts ($m) for Decernotinib, 2013-2023
  • Table 116: Product Profile - Filgotinib
  • Table 117: Filgotinib SWOT Analysis, 2014
  • Table 118: Global Sales Forecasts ($m) for Filgotinib, 2013-2023
  • Table 119: Product Profile - Masitinib
  • Table 120: ACR Response to Masitinib in RA (12 Weeks)
  • Table 121: ACR Responses for Masitinib in the Phase IIa ITT Population (12-82 Weeks)
  • Table 122: Masitinib SWOT Analysis, 2014
  • Table 123: Global Sales Forecasts ($m) for Masitinib, 2013-2023
  • Table 124: Product Profile - RAVAX
  • Table 125: RAVAX SWOT Analysis, 2014
  • Table 126: Drugs in Phase II of Development for RA, 2014
  • Table 127: Key Companies in the RA Market, 2014
  • Table 128: AbbVie's RA Portfolio Assessment, 2014
  • Table 129: Pfizers's RA Portfolio Assessment, 2014
  • Table 130: Amgen's RA Portfolio Assessment, 2014
  • Table 131: J&J's RA Portfolio Assessment, 2014
  • Table 132: Eli Lilly's RA Portfolio Assessment, 2014
  • Table 133: BMS' RA Portfolio Assessment, 2014
  • Table 134: UCB's RA Portfolio Assessment, 2014
  • Table 135: Roche's RA Portfolio Assessment, 2014
  • Table 136: GSK's RA Portfolio Assessment, 2014
  • Table 137: Novartis' RA Portfolio Assessment, 2014
  • Table 138: Sanofi's RA Portfolio Assessment, 2014
  • Table 139: AstraZeneca -MedImmune's RA Portfolio Assessment, 2014
  • Table 140: Astellas's RA Portfolio Assessment, 2014
  • Table 141: Vertex's RA Portfolio Assessment, 2014
  • Table 142: Daiichi Sankyo's RA Portfolio Assessment, 2014
  • Table 143: Global Sales Forecasts ($m) for RA, 2013-2023
  • Table 144: Global RA Market - Drivers and Barriers, 2013-2023
  • Table 145: Sales Forecasts ($m) for RA in the United States, 2013-2023
  • Table 146: Key Events Impacting Sales for RA in the US, 2013-2023
  • Table 147: RA Market in the US - Drivers and Barriers, 2013-2023
  • Table 148: Sales Forecasts ($m) for RA in France, 2013-2023
  • Table 149: Key Events Impacting Sales for RA in France, 2013-2023
  • Table 150: RA Market in France - Drivers and Barriers, 2013-2023
  • Table 151: Sales Forecasts ($m) for RA in Germany, 2013-2023
  • Table 152: Key Events Impacting Sales for RA in Germany, 2013-2023
  • Table 153: RA Market in Germany - Drivers and Barriers, 2013-2023
  • Table 154: Sales Forecasts ($m) for RA in Italy, 2013-2023
  • Table 155: Key Events Impacting Sales for RA in Italy, 2013-2023
  • Table 156: RA Market in Italy - Drivers and Barriers, 2013-2023
  • Table 157: Sales Forecasts ($m) for RA in Spain, 2013-2023
  • Table 158: Key Events Impacting Sales for RA in Spain, 2013-2023
  • Table 159: RA Market in Spain - Drivers and Barriers, 2013-2023
  • Table 160: Sales Forecasts ($m) for RA in the UK, 2013-2023
  • Table 161: Key Events Impacting Sales for RA in the UK, 2013-2023
  • Table 162: RA Market in the UK - Drivers and Barriers, 2013-2023
  • Table 163: Sales Forecasts ($m) for RA in Japan, 2013-2023
  • Table 164: Key Events Impacting Sales for RA in Japan, 2013-2023
  • Table 165: RA Market in Japan - Drivers and Barriers, 2013-2023
  • Table 166: Sales Forecasts ($m) for RA in Australia, 2013-2023
  • Table 167: Key Events Impacting Sales for RA in Australia, 2013-2023
  • Table 168: RA Market in Australia - Drivers and Barriers, 2013-2023
  • Table 169: Sales Forecasts ($) for RA in China, 2013-2023
  • Table 170: Key Events Impacting Sales for RA in China, 2013-2023
  • Table 171: RA Market in China - Drivers and Barriers, 2013-2023
  • Table 172: Sales Forecasts ($m) for RA in India, 2013-2023
  • Table 173: Key Events Impacting Sales for RA in India, 2013-2023
  • Table 174: RA Market in India - Drivers and Barriers, 2013-2023
  • Table 175: Key Launch Dates of RA Products in the 10MM
  • Table 176: Key Patent Expiries
  • Table 177: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Normal Synovial Joint and Synovial Joint with RA
  • Figure 2: Cellular and Cytokine Targets for the Current RA Drugs
  • Figure 3: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, 2013-2023
  • Figure 4: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N, 2013
  • Figure 5: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N, 2013
  • Figure 6: 10MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, 2013-2023
  • Figure 7: 10MM, Age-Standardized Prevalence of RA (%), Ages ≥18 Years, 2013
  • Figure 8: Disease Management Flowchart for Early RA - ACR 2012
  • Figure 9: Disease Management Flowchart for Established RA - ACR 2012
  • Figure 10: Flowchart for the Management of RA - EULAR 2013
  • Figure 11: Biosimilar Prescribing Habits in RA Across the 10MM, 2014
  • Figure 12: Global Sales Forecasts ($m) for Enbrel vs. Etanercept Biosimilars, 2013-2023
  • Figure 13: Global Sales Forecasts ($m) for Humira vs. Adalimumab Biosimilars, 2013-2023
  • Figure 14: Global Sales Forecasts ($m) for Remicade vs. Infliximab Biosimilars, 2013-2023
  • Figure 15: Global Sales Forecasts ($m) for Cimzia vs. Certolizumab Pegol Biosimilars, 2013-2023
  • Figure 16: Global Sales of Orencia vs. Abatacept (IV) Biosimilars, 2013-2023
  • Figure 17: Global Sales of Actemra vs. Tocilizumab (IV) Biosimilars, 2013-2023
  • Figure 18: Global Sales of Rituxan vs. Rituximab Biosimilars, 2013-2023
  • Figure 19: RA Clinical Trials - By Drug Class, 2014
  • Figure 20: RA - Phase II-III Pipeline, 2014
  • Figure 21: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013-2023
  • Figure 22: Clinical and Commercial Positioning of Sarilumab
  • Figure 23: Clinical and Commercial Positioning of Sirukumab
  • Figure 24: Clinical and Commercial Positioning of Clazakizumab
  • Figure 25: Clinical and Commercial Positioning of Cosentyx
  • Figure 26: Clinical and Commercial Positioning of Tregalizumab
  • Figure 27: Clinical and Commercial Positioning of Mavrilimumab
  • Figure 28: Clinical and Commercial Positioning of denosumab in RA
  • Figure 29: Clinical and Commercial Positioning of Baricitinib
  • Figure 30: Clinical and Commercial Positioning of Peficitinib
  • Figure 31: Clinical and Commercial Positioning of Decernotinib
  • Figure 32: Clinical and Commercial Positioning of Filgotinib
  • Figure 33: Clinical and Commercial Positioning of Masitinib
  • Figure 34: Clinical and Commercial Positioning of RAVAX
  • Figure 35: Company Portfolio Gap Analysis in RA, 2013-2023
  • Figure 36: AbbVie SWOT Analysis in RA, 2013-2023
  • Figure 37: Pfizer SWOT Analysis in RA, 2013-2023
  • Figure 38: Amgen SWOT Analysis in RA, 2013-2023
  • Figure 39: J&J SWOT Analysis in RA, 2013-2023
  • Figure 40: Eli Lilly SWOT Analysis in RA, 2013-2023
  • Figure 41: BMS SWOT Analysis in RA, 2013-2023
  • Figure 42: UCB SWOT Analysis in RA, 2013-2023
  • Figure 43: Roche SWOT Analysis in RA, 2013-2023
  • Figure 44: GSK SWOT Analysis in RA, 2013-2023
  • Figure 45: Novartis SWOT Analysis in RA, 2013-2023
  • Figure 46: Sanofi SWOT Analysis in RA, 2013-2023
  • Figure 47: AstraZeneca/MedImmune SWOT Analysis in RA, 2013-2023
  • Figure 48: Astellas SWOT Analysis in RA, 2013-2023
  • Figure 49: Vertex SWOT Analysis in RA, 2013-2023
  • Figure 50: Daiichi Sankyo SWOT Analysis in RA, 2013-2023
  • Figure 51: Global Sales for RA by Region, 2013-2023
  • Figure 52: Sales for RA in the United States by Drug Class, 2013-2023
  • Figure 53: Sales for RA in France by Drug Class, 2013-2023
  • Figure 54: Sales for RA in Germany by Drug Class, 2013-2023
  • Figure 55: Sales for RA in Italy by Drug Class, 2013-2023
  • Figure 56: Sales for RA in Spain by Drug Class, 2013-2023
  • Figure 57: Sales for RA in the UK by Drug Class, 2013-2023
  • Figure 58: Sales for RA in Japan by Drug Class, 2013-2023
  • Figure 59: Sales for RA in Australia by Drug Class, 2013-2023
  • Figure 60: Sales for RA in China by Drug Class, 2013-2023
  • Figure 61: Sales for RA in India by Drug Class, 2013-2023
Back to Top